ATEC

Alphatec Holdings, Inc.
CAPPED RATING

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.

Alphatec Holdings, Inc. (ATEC) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.8 / 5.0
Growth
B-
Factor Score 3.1 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 12.1
EV / EBITDA 30.0
Rev Growth YoY 12.6%
Gross Margin 71.3%
Price Return 3M -28.9%
Price Return 12M -66.4%
Catalyst Signal 0.00
Market Cap $1.0B
TTM Revenue $839.7M
Price / Sales 1.2
ROE -308.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.8) B- (3.1) C+ (2.8) C+ (2.7) F (0.0) C (2.3)
2026-11-10 C+ (2.6) B- (3.1) C+ (2.8) B- (3.0) F (0.0) C (2.3)
2026-11-03 C+ (2.7) B- (3.1) B- (2.9) C (2.2) C+ (2.7) C+ (2.7)
2026-10-27 C (2.3) B- (3.1) C+ (2.8) C+ (2.8) C+ (2.6) C+ (2.7)
2026-10-20 C (2.3) B- (3.1) C+ (2.8) C+ (2.8) C+ (2.6) C+ (2.7)
Page 1 of 7